These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 9120389)

  • 1. Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes.
    Theobald M; Biggs J; Hernández J; Lustgarten J; Labadie C; Sherman LA
    J Exp Med; 1997 Mar; 185(5):833-41. PubMed ID: 9120389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of HLA A2.1/p53 peptide tetramers to visualize the impact of self tolerance on the TCR repertoire.
    Hernández J; Lee PP; Davis MM; Sherman LA
    J Immunol; 2000 Jan; 164(2):596-602. PubMed ID: 10623800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of T cells specific for the wild-type sequence p53(264-272) peptide in cancer patients: implications for immunoselection of epitope loss variants.
    Hoffmann TK; Nakano K; Elder EM; Dworacki G; Finkelstein SD; Appella E; Whiteside TL; DeLeo AB
    J Immunol; 2000 Nov; 165(10):5938-44. PubMed ID: 11067956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Partial tyrosinase-specific self tolerance by HLA-A*0201-restricted cytotoxic T lymphocytes in mice and man.
    Lotz C; Ferreira EA; Drexler I; Mutallib SA; Huber C; Sutter G; Theobald M
    Int J Cancer; 2004 Feb; 108(4):571-9. PubMed ID: 14696122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of transgenic mice to generate high affinity p53 specific cytolytic T cells.
    Yu Z; Liu X; McCarty TM; Diamond DJ; Ellenhorn JD
    J Surg Res; 1997 May; 69(2):337-43. PubMed ID: 9224403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro generated cytolytic T lymphocytes reactive against head and neck cancer recognize multiple epitopes presented by HLA-A2, including peptides derived from the p53 and MDM-2 proteins.
    Asai T; Storkus WJ; Mueller-Berghaus J; Knapp W; DeLeo AB; Chikamatsu K; Whiteside TL
    Cancer Immun; 2002 Apr; 2():3. PubMed ID: 12747748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ability of variant peptides to reverse the nonresponsiveness of T lymphocytes to the wild-type sequence p53(264-272) epitope.
    Hoffmann TK; Loftus DJ; Nakano K; Maeurer MJ; Chikamatsu K; Appella E; Whiteside TL; DeLeo AB
    J Immunol; 2002 Feb; 168(3):1338-47. PubMed ID: 11801674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of cytotoxic T cell responses to an HLA-A24 restricted epitope peptide derived from wild-type p53.
    Umano Y; Tsunoda T; Tanaka H; Matsuda K; Yamaue H; Tanimura H
    Br J Cancer; 2001 Apr; 84(8):1052-7. PubMed ID: 11308253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mice expressing the E7 oncogene of HPV16 in epithelium show central tolerance, and evidence of peripheral anergising tolerance, to E7-encoded cytotoxic T-lymphocyte epitopes.
    Doan T; Chambers M; Street M; Fernando GJ; Herd K; Lambert P; Tindle R
    Virology; 1998 May; 244(2):352-64. PubMed ID: 9601506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells.
    Chikamatsu K; Nakano K; Storkus WJ; Appella E; Lotze MT; Whiteside TL; DeLeo AB
    Clin Cancer Res; 1999 Jun; 5(6):1281-8. PubMed ID: 10389910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytotoxic T lymphocyte responses to wild-type and mutant mouse p53 peptides.
    Bertholet S; Iggo R; Corradin G
    Eur J Immunol; 1997 Mar; 27(3):798-801. PubMed ID: 9079825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxic T lymphocyte recognition of HLA-A2 antigens in normal and HLA-Cw3-transgenic mice.
    Hämmerling GJ; Hunt T; Dill O; Moreno J
    Eur J Immunol; 1989 Apr; 19(4):599-604. PubMed ID: 2786469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased frequencies of CD8+ T lymphocytes recognizing wild-type p53-derived epitopes in peripheral blood correlate with presence of epitope loss tumor variants in patients with hepatocellular carcinoma.
    Cicinnati VR; Zhang X; Yu Z; Ferencik S; Schmitz KJ; Dworacki G; Kaczmarek E; Oldhafer K; Frilling A; Baba HA; Schmid KW; Grosse-Wilde H; Broelsch CE; DeLeo AB; Gerken G; Beckebaum S
    Int J Cancer; 2006 Dec; 119(12):2851-60. PubMed ID: 16998881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dendritic cells transduced with full-length wild-type p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patients.
    Nikitina EY; Clark JI; Van Beynen J; Chada S; Virmani AK; Carbone DP; Gabrilovich DI
    Clin Cancer Res; 2001 Jan; 7(1):127-35. PubMed ID: 11205900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of CD8+ cytotoxic T lymphocyte/tumor cell interactions reflecting recognition of an endogenously expressed murine wild-type p53 determinant.
    Hilburger Ryan M; Abrams SI
    Cancer Immunol Immunother; 2001 Jan; 49(11):603-12. PubMed ID: 11225991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HLA-A2.1/K(b) transgenic murine dendritic cells transduced with an adenovirus encoding human gp100 process the same A2.1-restricted peptide epitopes as human antigen-presenting cells and elicit A2.1-restricted peptide-specific CTL.
    Yang S; Linette GP; Longerich S; Roberts BL; Haluska FG
    Cell Immunol; 2000 Aug; 204(1):29-37. PubMed ID: 11006015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunological characterization of missense mutations occurring within cytotoxic T cell-defined p53 epitopes in HLA-A*0201+ squamous cell carcinomas of the head and neck.
    Ito D; Visus C; Hoffmann TK; Balz V; Bier H; Appella E; Whiteside TL; Ferris RL; DeLeo AB
    Int J Cancer; 2007 Jun; 120(12):2618-24. PubMed ID: 17294448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Presentation of a horse cytochrome c peptide by multiple H-2b class I major histocompatibility complex (MHC) molecules to C57BL/6- and bm1-derived cytotoxic T lymphocytes: presence of a single MHC anchor residue may confer efficient peptide-specific CTL recognition.
    Sheil JM; Schell TD; Shepherd SE; Klimo GF; Kioschos JM; Paterson Y
    Eur J Immunol; 1994 Sep; 24(9):2141-9. PubMed ID: 7522163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A wild-type p53 cytotoxic T cell epitope is presented by mouse hepatocarcinoma cells.
    Lacabanne V; Viguier M; Guillet JG; Choppin J
    Eur J Immunol; 1996 Nov; 26(11):2635-9. PubMed ID: 8921949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A HLA-A2 restricted human CTL line recognizes a novel tumor cell expressed p53 epitope.
    Würtzen PA; Claesson MH
    Int J Cancer; 2002 Jun; 99(4):568-72. PubMed ID: 11992547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.